← Evidence library Mechanism of action De novo NAD+ via kynurenine pathway (60 mg Trp -> 1 mg niacin equivalent) Serotonin precursor Melatonin precursor Molecular + tissue targets NAD+ pool (kynurenine route) Serotonin synthesis Melatonin synthesis TDO/IDO enzymes Dosage range 5 mg/kg/day RDA · 500-2000 mg/day mood/sleep (caution SSRI interaction · Tier C · Arnone 2018 PMID 29940237 kynurenine pathway mood SR+MA)
Safety notes Drug interaction with SSRI/MAOI (serotonin syndrome risk) · pregnancy generally safe at RDA · 1989 EMS outbreak associated with contaminated supplement (not pure tryptophan)
Cross-market regulatory status 🇺🇸 FDA GRAS (amino acid food ingredient · post-1995 reinstatement)
🇪🇺 EFSA Reg 432/2012 rejected mood claims 2010 · no authorized health claim
🇧🇷 ANVISA RDC 243/2018 dietary supplement framework · IN 28/2018 no Anexo V claim
Evidence anchors (PubMed) · 2 Arnone D (2018) Neurosci Biobehav Rev
Role of Kynurenine Pathway and its Metabolites in Mood Disorders: A Systematic Review and Meta-Analysis of Clinical Studies
SR+MA kynurenine pathway dysregulation in mood disorders (not tryptophan supplementation directly · documents pathway alterations in depression) · verified 2026-06-07 · PMCID PMC6686193
Hunt C (2020) Neurosci Biobehav Rev
Effect of immune activation on the kynurenine pathway and depression symptoms - A systematic review and meta-analysis
SR+MA immune activation kynurenine pathway depression symptoms (not direct tryptophan intervention) · verified 2026-06-07 · PMCID PMC8087452
Common use cases mood support (educational · evidence mixed) sleep support NAD+ alternate precursor